Biote Corp Q4 Revenue Falls 6.9% While Supplement Sales Rise 16%
Biote Corp expanded its commercial team from about 60 to over 90 salespeople by end-2025 and grew dietary supplement revenue 16% through e-commerce expansion. Q4 total revenue fell 6.9%, procedure revenue dropped 13%, and adjusted EBITDA declined to $11.7M on a 25.2% margin following a $1.3M recall charge.
1. Commercial and E-commerce Growth
Biote Corp rebuilt its commercial team, increasing headcount from approximately 60 to over 90 salespeople by the end of 2025 and targeting about 120 by the end of Q1 2026. This expansion supported a 16% increase in dietary supplement revenue, driven primarily by growth in its e-commerce channel.
2. Revenue and Segment Performance
Total fourth-quarter revenue declined 6.9% year-over-year, with procedure revenue down 13% due to fewer net new clinic additions and lower procedure volumes. Conversely, dietary supplement sales grew, reflecting the company’s strategic shift toward online and retail channels.
3. Margin Impact and Recall Charge
Gross profit margin compressed from 71.8% to 68.0%, pressured by a $1.3 million inventory charge related to a voluntary product recall. Adjusted EBITDA fell to $11.7 million, representing a 25.2% margin compared to $15.1 million and a 30.3% margin a year earlier.
4. Outlook and Strategic Initiatives
Biote anticipates a mid- to high-single-digit decline in procedure revenue in the first half of 2026, partly due to recall-related disruptions. The company is investing in its technology platform and practitioner training to improve retention and support future volume recovery.